TD Cowen Maintains Septerna(SEPN.US) With Buy Rating

TD Cowen維持Septerna(SEPN.US)買入評級

moomoo資訊 · 11/20 11:31 · 評級/大行評級

TD Cowen analyst Yaron Werber maintains $Septerna (SEPN.US)$ with a buy rating.

According to TipRanks data, the analyst has a success rate of 53.0% and a total average return of 11.4% over the past year.

AnalystRecentRatingAutoNews_85968065642102_20241120_6a3c31a07a4dbb5ccd0ca09eb0e9a281c7a7611c_1732185146891760_mm_en

Furthermore, according to the comprehensive report, the opinions of $Septerna (SEPN.US)$'s main analysts recently are as follows:

Septerna is noted for its unique position within the broader biopharma landscape, by deploying predictive high-throughput screening along with SAR optimization focussed on G protein-coupled receptor targets. The company's strategic execution of a highly attractive pipeline, targeting validated entities in substantial, established indications where an oral option presents a clear advantage to patients, is particularly noteworthy.
There is potential upside for the shares based on the Phase 1 results of SEP-786, considered to be promising due to existing data from similar parathyroid hormone programs. Septerna's SEP-631 is regarded as a significant but unrecognized asset. The company's Native Complex platform approach and the preclinical data of SEP-786 are expected to effectively transition into clinical stages.
The company is leveraging its Native Complex platform to develop a pipeline of oral small molecule G protein-coupled receptor drugs. There is seen as significant potential for stock appreciation rooted in validated targets within sizable markets.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

TD Cowen分析師Yaron Werber維持$Septerna (SEPN.US)$買入評級。

根據TipRanks數據顯示，該分析師近一年總勝率為53.0%，總平均回報率為11.4%。

AnalystRecentRatingAutoNews_85968065642102_20241120_6a3c31a07a4dbb5ccd0ca09eb0e9a281c7a7611c_1732185146891760_mm_tc

此外，綜合報道，$Septerna (SEPN.US)$近期主要分析師觀點如下：

Septerna以其在更廣泛的生物製藥領域中的獨特地位而聞名，它部署了預測性高通量篩選以及側重於G蛋白偶聯受體靶標的SAR優化。該公司戰略性地執行了一條極具吸引力的產品線，該產品線針對的是經過驗證的實體，在這些適應症中，口服期權對患者具有明顯的優勢。
根據 SEP-786 的第一階段業績，該股可能有上漲空間，由於來自類似甲狀旁腺激素計劃的現有數據，該股被認爲前景樂觀。Septerna的 SEP-631 被視爲一項重要但未被認可的資產。該公司的 Native Complex 平台方法和 SEP-786 的臨床前數據有望有效地過渡到臨床階段。
該公司正在利用其Native Complex平台開發口服小分子G蛋白偶聯受體藥物管道。股票升值的巨大潛力被視爲龐大市場中經過驗證的目標。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

TD Cowen Maintains Septerna(SEPN.US) With Buy Rating

TD Cowen Maintains Septerna(SEPN.US) With Buy Rating

風險及免責聲明

聲明